查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球风湿病治疗市场 2023-2030
市场调查报告书
商品编码
1351027

全球风湿病治疗市场 2023-2030

Global Rheumatology Therapeutics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期内（2023-2030年）全球市场将以3.2%的复合年增长率成长。治疗药物用于减缓某些自体免疫性风湿性疾病的进展，例如风湿性关节炎（RA）。 RA在全球的盛行率不断上升，促进了新型治疗药物的推出，而针对高成本治疗产品的有利翻新政策是推动市场成长的一些因素。根据美国国立卫生研究院 (NIH) 的数据，2023 年 5 月，女性患风湿性关节炎的比例高于男性，女性终生患风湿性关节炎的风险为 3.6%，而男性为 1.7%。 RA 风险也随着年龄的增长而增加，发病高峰在 65 岁至 80 岁之间。此外，新型生物药物上市率的上升、仿製药的批准增加和渗透率的不断提高，为风湿病治疗市场带来了盈利机会。例如，2022 年6 月，安进宣布FDA 批准Rituxan (R) 的生物相似药RIABNI (TM) (rituximab-arrx) 与甲氨蝶呤联合治疗患有中度至重度活动性类风湿性关节炎( RA) 的成人患者。对一种或多种肿瘤坏死因子 (TNF) 拮抗剂治疗反应不足。

细分市场前景

全球风湿病治疗市场按药物类型、疾病适应症、类别和分销管道进行细分。根据药物类型，市场细分为缓解疾病的抗风湿药、非类固醇类抗发炎药、皮质类固醇、降尿酸药等。根据疾病适应症，市场细分为类风湿性关节炎、骨关节炎、痛风、干癣性关节炎和僵直性脊椎炎。根据类别，市场分为处方药和非处方药。此外，根据分销管道，市场分为医院药房、零售药房和网路药房。在疾病适应症中，由于基于成簇规则间隔短回文重复序列（CRISPR）/Cas9的基因组编辑、RNA干扰、PROTAC等新技术的发展，预计类风湿性关节炎细分市场将占据相当大的市场份额（蛋白水解靶向嵌合体）和基于人工智慧（AI）的药物设计能够筛选标靶疗法。

疾病缓解抗风湿药物 (DMARD) 预计将在全球风湿病治疗市场中占据相当大的份额

在该药物类型中，该细分市场预计将在全球风湿病治疗市场中占据相当大的份额。这一细分市场的成长归因于 DMARD 利用率的增加以及全球 RA 发生率的上升。例如，根据国家生物技术资讯中心的数据，2022 年 6 月，美国和北欧其他西方国家的 RA 年发生率约为每 10 万人中 40 例。由于人们对 RA 治疗方案的认识激增。

区域展望

全球风湿病治疗市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本） 、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于类风湿性关节炎的盛行率不断增加，人们对该疾病的认识不断提高，并且患病率的增加加上先进的类风湿性关节炎疗法的采用，预计亚太地区将占据显着的市场占有率。市场成长。主要市场参与者包括中外製药有限公司、Dr Reddy's Laboratories Ltd. LG Chem、Lupin Ltd、Taisho Pharmaceutical Holdings Co., Ltd.等。

北美地区预计全球风湿病治疗市场复合年增长率显着成长

在所有地区中，北美地区预计在预测期内将以相当大的复合年增长率成长。该区域市场的成长归因于人们对风湿病早期诊断和治疗的认识不断提高，以及越来越多地使用 DMARD 进行治疗。此外，新型生物药物上市的增加、仿製药的批准增加和渗透率的不断提高，为风湿病治疗市场参与者带来了盈利机会。例如，2023 年7 月，Biocon Ltd. 的子公司Biocon Biologics Ltd (BBL) 宣布，经过在欧洲使用5 年和在加拿大使用两年后，HULIO (R) (adalimumab-fkjp) 注射剂（一种生物仿製药） Humira (R)（阿达木单抗）现已可供美国患者使用。

市场参与者展望

服务全球风湿病治疗市场的主要公司包括： F. Hoffmann-La Roche Ltd.、Johnson & Johnson Private Ltd.、Merck & Co., Inc.、Novartis AG、Pfizer Inc.等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 1 月，吉利德科学公司 (Gilead Sciences, Inc.) 和 EVOQ Therapeutics, Inc. 签订许可协议进行合作，推进 EVOQ 用于治疗类风湿性关节炎 (RA) 和狼疮的专有技术。 EVOQ 的 NanoDisc 技术旨在实现疾病特异性抗原的淋巴靶向递送，并有可能改变自体免疫疾病的治疗模式。

报告涵盖：

  • 2022年市场价​​值数据分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球风湿病治疗市场的主要公司。根据现有数据，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Merck & Co., Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Novartis AG
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Pfizer Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按药物类型分類的全球风湿病治疗市场
    • 缓解疾病的抗风湿药物
    • 非类固醇抗发炎药
    • 皮质类固醇
    • 降尿酸药物
    • 其他的
  • 按疾病适应症分類的全球风湿病治疗市场
    • 类风湿关节炎
    • 骨关节炎
    • 痛风
    • 银屑病关节炎
    • 僵直性脊椎炎
  • 全球风湿病治疗市场按类别
    • 处方
    • 场外交易 (OTC)
  • 按分销管道分類的全球风湿病治疗市场
    • 医院药房
    • 零售药房
    • 网路药房

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Private Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi, Genentech, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • UCB S.A.
Product Code: OMR2027627

Title: Global Rheumatology Therapeutics Market Size, Share & Trends Analysis Report by Drug Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis), by Category (Prescription and Over-the-Counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy),Forecast Period (2023-2030).

The global market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Segmental Outlook

The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.

The Disease-modifying Anti-rheumatic Drugs (DMARDs) Sub-Segment is Anticipated to Hold a Considerable Share of the Global Rheumatology Therapeutics Market

Among the drug type, the sub-segment is expected to hold a considerable share of the global rheumatology therapeutics market. The segmental growth is attributed to the increased utilization of DMARD coupled with the rising incidence of RA around the globe. For instance, according to the National Center for Biotechnology Information, in June 2022, the annual incidence of RA in the US and other Western nations of northern Europe is about 40 per 100,000 persons. Owing to a surge in awareness related to treatment options available for RA.

Regional Outlook

The global rheumatology therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market, owing to the increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive market growth. The key market player includes Chugai Pharmaceutical Co., Ltd., Dr Reddy's Laboratories Ltd. LG Chem, Lupin Ltd, Taisho Pharmaceutical Holdings Co., Ltd., and others.

The North America Region is Expected to Grow at a Significant CAGR in the Global Rheumatology Therapeutics Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing awareness regarding the early diagnosis and treatment of rheumatology disease and the increasing use of DMARD's for treating. Furthermore, the rise in launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players. For instance, in July 2023, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., announced that after 5 years of use in Europe and two years in Canada, HULIO® (adalimumab-fkjp) injectable, a biosimilar to Humira® (adalimumab), is now accessible to patients in the US.

Market Players Outlook

The major companies serving the global rheumatology therapeutics market include: F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. collaborated along with a licensing agreement to advance EVOQ's proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ's NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Merck & Co., Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rheumatology Therapeutics Market by Drug Type
    • 4.1.1. Disease-Modifying Anti-Rheumatic Drugs
    • 4.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 4.1.3. Corticosteroids
    • 4.1.4. Uric Acid Drugs
    • 4.1.5. Others
  • 4.2. Global Rheumatology Therapeutics Market by Disease Indication
    • 4.2.1. Rheumatoid Arthritis
    • 4.2.2. Osteoarthritis
    • 4.2.3. Gout
    • 4.2.4. Psoriatic Arthritis
    • 4.2.5. Ankylosing Spondylitis
  • 4.3. Global Rheumatology Therapeutics Market by Category
    • 4.3.1. Prescription
    • 4.3.2. Over-the-Counter (OTC)
  • 4.4. Global Rheumatology Therapeutics Market by Distribution Channel
    • 4.4.1. Hospital Pharmacy
    • 4.4.2. Retail Pharmacy
    • 4.4.3. Online Pharmacy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. AstraZeneca plc
  • 6.4. Aurinia Pharmaceuticals Inc.
  • 6.5. Boehringer Ingelheim International GmbH
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Eli Lilly
  • 6.8. F. Hoffmann-La Roche Ltd.
  • 6.9. Gilead Sciences, Inc.
  • 6.10. Janssen Pharmaceuticals, Inc.
  • 6.11. Johnson & Johnson Private Ltd.
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sanofi, Genentech, Inc.
  • 6.14. Takeda Pharmaceutical Company Ltd.
  • 6.15. UCB S.A.

LIST OF TABLES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022 VS 2030 (%)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022 VS 2030 (%)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 21. US RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. UK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)